Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine. 2008; 26(7):882-90. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007; 5(7):518-28. Blaney JE, Jr., Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006; 19:10-32. Durbin AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar B, Wanionek K, Murphy BR, Whitehead SS. rDEN2/4Delta30(ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults. Hum Vaccin. 2006; 2(6):255-260. Durbin AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1?30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccin. 2006; 2(4):167-173. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr., Thumar B, Murphy BR, Karron RA. rDEN4?30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005; 191:710-718. Durbin AP, Karron RA, Thumar B, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. A live attenuated dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in the 3´ untranslated region is highly attenuated and immunogenic in humans. Am J Trop Med Hyg. 2001; 65:405-413. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR. A live attenuated dengue-4 virus vaccine candidate with a 30 base pair deletion in its 3´ untranslated region has restricted capacity for dissemination in mosquitoes and is not transmitted from vaccinees to mosquitoes. Am J Trop Med Hyg. 2001; 65:414-419.
|
